文献速递神经核医学核素与放射性配体治疗

68Ga-戊柔肽PET/CT在库欣综合征诊断与管理中的价值

Usefulness of 68 Ga-Pentixafor PET/CT on Diagnosis and Management of Cushing Syndrome.
PubMed 文献 · Clin Nucl Med · 2022-04-22

本初步研究回顾性评估31例患者(16例库欣综合征、15例无功能垂体或肾上腺腺瘤),采用68Ga-戊柔肽PET/CT检测CXCR4分子影像。结果显示肾上腺病变SUVmax>8.5诊断皮质醇分泌腺瘤的灵敏度和特异度分别为100%和84.9%,垂体腺瘤SUVmax 3.0鉴别ACTH分泌性垂体腺瘤的灵敏度和特异度均为100%;激素水平与垂体及肾上腺组织摄取显著相关,但与葡萄糖代谢无关。

要点

  • 68Ga-戊柔肽PET/CT在库欣综合征不同亚型中具有特征性摄取表现。
  • 肾上腺病变SUVmax>8.5诊断皮质醇分泌腺瘤灵敏度100%、特异度84.9%。
  • 垂体腺瘤SUVmax 3.0鉴别ACTH分泌性垂体腺瘤灵敏度与特异度均为100%。

核心结论

  • 68Ga-戊柔肽PET/CT在ACTH非依赖性及ACTH依赖性库欣综合征的鉴别诊断中有应用前景。
  • 库欣病患者沿垂体-肾上腺轴存在活化的CXCR4分子信号。

研究设计与样本

  • 本初步研究回顾性评估31例患者,其中库欣综合征16例、无功能垂体或肾上腺腺瘤15例。
  • 所有患者接受68Ga-戊柔肽PET/CT,其中11例垂体腺瘤患者还接受18F-FDG PET/CT。
  • 计算68Ga-戊柔肽PET/CT的诊断准确率及垂体-肾上腺轴放射性摄取与激素水平的相关性。

主要发现

  • 库欣病表现为ACTH分泌性垂体腺瘤局灶性摄取。
  • ACTH非依赖性库欣综合征中肾上腺病变68Ga-戊柔肽摄取增高,而垂体窝无摄取增高。
  • 无功能垂体或肾上腺腺瘤显示68Ga-戊柔肽信号阴性。
  • 1例转移性异位ACTH综合征患者有多发68Ga-戊柔肽高摄取病灶。
  • 相应激素水平与垂体腺瘤及肾上腺组织68Ga-戊柔肽摄取显著相关,但与葡萄糖代谢无显著相关。

关键数值与推荐

  • 肾上腺病变SUVmax>8.5时,68Ga-戊柔肽PET/CT诊断皮质醇分泌腺瘤的灵敏度100%、特异度84.9%。
  • 68Ga-戊柔肽PET/CT SUVmax cutoff值3.0鉴别ACTH分泌性垂体腺瘤的灵敏度与特异度均为100%。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This pilot study investigated the performance of C-X-C motif chemokine receptor 4 (CXCR4) molecular imaging ( 68 Ga-pentixafor PET/CT) in Cushing syndrome (CS) and the correlation between CXCR4 signaling interactions and glucose metabolism in adrenocorticotropin-cortisol pathway. METHODS: We retrospectively evaluated 31 patients (16 patients with CS and 15 patients with nonfunctioning pituitary or adrenal adenomas). All patients underwent 68 Ga-pentixafor PET/CT, and 11 with pituitary adenoma also underwent 18 F-FDG PET/CT. The diagnosis accuracy of 68 Ga-pentixafor PET/CT was calculated. The correlation between radiouptake along the pituitary-adrenal axis and hormone levels was calculated. RESULTS: Patients with Cushing disease characterized a focal uptake in adrenocorticotropic hormone-producing pituitary adenoma (ACTH-PA). In ACTH-independent CS, there was increased uptake of 68 Ga-pentixafor in adrenal lesions but not in the pituitary fossa. The nonfunctioning pituitary or adrenal adenomas showed negative 68 Ga-pentixafor signal. The one patient with metastatic ectopic ACTH syndrome had multiple 68 Ga-pentixafor-avid lesions. Using the threshold of SUV max >8.5 in the adrenal lesions, the sensitivity and specificity of 68 Ga-pentixafor PET/CT to diagnose cortisol-producing adenoma were 100% and 84.9%. A cutoff SUV max value of 3.0 on 68 Ga-pentixafor PET/CT had 100% sensitivity and specificity for differentiating ACTH-PA. The corresponding hormone level was significantly correlated with uptake of 68 Ga-pentixafor in pituitary adenoma and adrenal tissue but not with glucose metabolism. CONCLUSION: We have characterized the performance of 68 Ga-pentixafor in different subtypes of CS. 68 Ga-pentixafor PET/CT is promising in the differential diagnosis of both ACTH-independent and ACTH-dependent CS. Activated CXCR4 molecular signaling along the pituitary-adrenal axis was found in patients with Cushing disease.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ding J, Tong A, Hacker M, et al. Usefulness of 68 Ga-Pentixafor PET/CT on Diagnosis and Management of Cushing Syndrome. Clin Nucl Med. 2022. PMID: 35452014. doi:10.1097/RLU.0000000000004244

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。